List view / Grid view
National Cancer Institute (NCI)
6 June 2018 | By European Pharmaceutical Review
A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
2 April 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A randomised clinical trial shows that the drug sorafenib tosylate extended progression-free survival compared with a placebo...